MorphoSys received a milestone payment from Janssen
Janssen has Expanded Clinical Development of Guselkumab into Familial Adenomatous Polyposis
17-Apr-2019 -
MorphoSys AG announced that its licensee Janssen Research & Development, LLC, has further expanded the clinical development of guselkumab (Tremfya(R)) into familial adenomatous polyposis (FAP), a disease of the gastrointestinal tract.
Janssen has initiated a phase 1b proof-of-concept clinical ...
colon cancer
familial adenomatous polyposis
gastrointestinal diseases
+2